---
layout: default
title: Theophylline
parent: Model Prediction Only (L5)
nav_order: 821
evidence_level: L5
indication_count: 7
---

# Theophylline
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **7** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Theophylline: From Bronchodilator Therapy (Asthma/COPD) to Predicted Thrombotic Disease

## One-Sentence Summary

Theophylline is a classic methylxanthine bronchodilator, long used internationally for asthma and chronic obstructive pulmonary disease (COPD), though this original indication is not captured in the structured regulatory data for this evidence pack (data gap).
The TxGNN model's top-ranked prediction for this drug is **Thrombotic Disease** (score 99.62%), but the supporting evidence is currently very thin — **0 clinical trials** and **20 publications**, most of which are indirect background studies on platelet biomarkers rather than direct evidence of an antithrombotic effect.
Overall confidence in this specific candidate is low; a separate candidate in this same evidence pack (obstructive lung disease, rank 5) has far stronger clinical evidence and is not covered by this report.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in structured regulatory data (data gap); internationally recognized as a bronchodilator for asthma/COPD based on literature context in this pack |
| Predicted New Indication | Thrombotic Disease |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for theophylline is not available in this evidence pack. Based on general pharmacological knowledge, theophylline is a non-selective phosphodiesterase (PDE) inhibitor and adenosine receptor antagonist, a mechanism well established for its bronchodilator and anti-inflammatory effects in asthma/COPD (see literature in the "obstructive lung disease" candidate elsewhere in this pack).

The link to thrombotic disease is mechanistically speculative rather than established: PDE inhibition can theoretically raise intracellular cAMP in platelets and reduce platelet activation, which is the rationale behind several approved antiplatelet/vasodilator drugs (e.g., cilostazol). However, none of the literature identified for this candidate directly tests theophylline's effect on thrombosis or platelet aggregation in a treatment context — most articles use theophylline incidentally (e.g., as a component of anticoagulant/reagent buffers in laboratory assays) rather than as a therapeutic agent under study.

As stated in the underlying evidence review: *"Literature is mostly background research on platelet biomarkers/inflammatory mechanisms; there is no proof that theophylline directly inhibits thrombus formation. PDE inhibitors could theoretically affect platelet activation, but there is no clinical validation pathway."* This places the candidate at evidence level L5 with no clinical trial support.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [6771102](https://pubmed.ncbi.nlm.nih.gov/6771102/) | 1980 | Review | CRC Crit Rev Biochem | Reviews thromboxane A2/prostacyclin balance in platelet aggregation and atherosclerosis; does not address theophylline directly |
| [21719422](https://pubmed.ncbi.nlm.nih.gov/21719422/) | 2011 | Cohort/Ex vivo | Rheumatology (Oxford) | Platelet/neutrophil activation ex vivo in Behçet's disease patients; theophylline not a study drug |
| [15475744](https://pubmed.ncbi.nlm.nih.gov/15475744/) | 2004 | Cohort | Inflammatory Bowel Diseases | Platelet-leukocyte aggregate formation in IBD linked to thrombotic risk; theophylline not administered |
| [8055680](https://pubmed.ncbi.nlm.nih.gov/8055680/) | 1994 | PK study (ticlopidine) | Clinical Pharmacokinetics | Reviews antiplatelet drug ticlopidine pharmacokinetics; theophylline not the subject |
| [32824700](https://pubmed.ncbi.nlm.nih.gov/32824700/) | 2020 | Methodology study | Cells | Evaluates anticoagulation/sample-processing effects on platelet-derived microRNA signatures; theophylline not a treatment variable |
| [25856065](https://pubmed.ncbi.nlm.nih.gov/25856065/) | 2015 | Assay development | Platelets | Develops sCLEC-2 assay to detect platelet activation in thrombotic disease risk; theophylline not tested |
| [749930](https://pubmed.ncbi.nlm.nih.gov/749930/) | 1978 | Assay development | British Journal of Haematology | Describes PF4 radioimmunoassay; theophylline used only as a component of the anticoagulant reagent, not as treatment |
| [26764324](https://pubmed.ncbi.nlm.nih.gov/26764324/) | 2016 | In vitro study | The Journal of Nutrition | Aged garlic extract inhibits platelet aggregation via cAMP/cGMP pathways; theophylline not studied |
| [6241135](https://pubmed.ncbi.nlm.nih.gov/6241135/) | 1984 | Cohort (historical) | Cor et Vasa | Describes "theophylline-resistant" T-lymphocyte subsets elevated in vascular disease patients; immunological marker only, not a treatment study |
| [8981060](https://pubmed.ncbi.nlm.nih.gov/8981060/) | 1996 | In vitro pharmacology | General Pharmacology | Studies milrinone/adenosine interplay in platelet inhibition via cAMP; theophylline not the primary agent |

## India Market Information

Currently no registration information available — this drug is not marketed in India according to the available regulatory data.

## Safety Considerations

**Drug Interactions**: A total of 371 documented drug-drug interactions were identified for theophylline. Notable examples from the available sample include:
- **Major**: Bupropion
- **Moderate**: Famotidine, Ranitidine, Rabeprazole, Doxycycline, Hydrocortisone, Triamcinolone, Omeprazole, Dexamethasone, Betamethasone, Tetracycline, Budesonide, Cimetidine, Clarithromycin, Minocycline, Activated charcoal
- **Minor**: Ephedrine, Ephedrine (nasal)

Given the very high total interaction count (371), theophylline's known narrow therapeutic index should be assumed even where specific label warnings and contraindications are not yet available in this system (see data gaps below).

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN score for thrombotic disease is high, but there is no clinical trial evidence and the supporting literature is almost entirely indirect (platelet biomarker/assay studies), with no article directly evaluating theophylline as a treatment for thrombotic disease. This corresponds to evidence level L5 / decision stage S0, insufficient to support further development at this time.

**To proceed, the following is needed:**
- Regulatory label warnings and contraindications for theophylline (currently a **blocking** data gap — needed before any S1 safety screening can occur)
- Confirmed mechanism-of-action data (currently a **high-severity** data gap affecting mechanistic-linkage analysis)
- Dedicated preclinical or clinical studies directly testing theophylline's antithrombotic/antiplatelet activity, rather than incidental appearances in unrelated platelet biomarker research
- Note: this same evidence pack contains a substantially better-supported candidate — **obstructive lung disease** (rank 5, evidence level L1, decision stage S3, "Proceed with Guardrails") — which may warrant its own dedicated evaluation report rather than being deprioritized in favor of the top TxGNN-ranked but weakly supported thrombotic disease candidate.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

